International consulting and scientific services in Market Access Strategy, Health Economics&Outcomes Research, and Pricing.

Strategy

To perform an early phase feasibility analysis in order to identify the key clinical and economic issues for a successful launch of pharmaceutical, device or nutrition in the key markets, including clinical , health economic and legal hurdles. 

Early phase pricing models for developing pricing strategy and early-phase health economic models for cost-effectiveness assessment.  

To create the overall strategy for pricing and reimbursement ensuring that the position is consistent with US and European markets, including optimal positioning and pricing, cost-effectiveness and equity criteria.  

To develop value proposition for payers in each country as part of the planning activities, including the need for cost-effectiveness outcomes.

Market Access

The preparation of the project plan and reimbursement dossier for submission in each country and manage timing and communications with the relevant agencies.  

The development of key components of the reimbursement dossier: clinical section, cost-effectiveness and budget impact section. We will ensure that the clinical part of the reimbursement dossier and the economic parts are aligned, especially with regard to the claims, comparator(s) and value messages.    

Development of multicountry health economic models and country-specific model adaptations for existing models including the full spectrum of diseases for all countries.

Medical writing for clinical sections in reimbursement dossiers.

• Development of global core models:
  • Cost-effectiveness models: Markov models, Decision Tree Models
  • Budget impact analyses for financial analyses
• Adaptation of global health economics models to local conditions prevailing in other countries
• Preparation of health economics dossiers for applications to the reimbursement benefits boards